Exploring a Treatment Option for a Certain Subset of Patients with Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC)

Sponsored by Astellas Pharma US, Inc. and Pfizer Inc.

On-Demand iPub® Will Discuss a Treatment Option Available for a Certain Subset of Patients With Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC).

Hear experts in urology and oncology discuss a treatment option that may be appropriate for a certain subset of patients with nmCSPC. During this on-demand presentation, you will learn more about the risk factors, prognosis, and an available treatment option for a certain subset of patients with nmCSPC.

To obtain clinical expert insights and learn how this therapy can impact your patients and practice, watch on demand here.

This is a promotional program sponsored by Astellas Pharma US, Inc. and Pfizer Inc. The speakers have entered into a written agreement and have been compensated for their services in connection with this program. The information presented is consistent with FDA guidelines and is not approved for continuing medical education credit.

© 2024 Astellas Pharma Inc. or its affiliates and Pfizer Inc. All rights reserved. MAT-US-NPR-2024-00074 11/24